Terms: = Liver cancer AND PR, PGR, progesterone receptor AND Prognosis
232 results:
1. Surgical treatment improves overall survival of hepatocellular carcinoma with extrahepatic metastases after conversion therapy: a multicenter retrospective study.
Zhang X; Zhu X; Zhong J; Zhao Y; Zhang X; Zhang W; Ye F; Yang C; Xue J; Xiong R; Wang J; Shen S; Pan Y; Li D; Song T; Bi X; Sun H; Xiang B; Gu S; Wen T; Lu S; Chen Y; Yin T; Liu L; Kuang M; Xu L; Li D; Cai J
Sci Rep; 2024 Apr; 14(1):9745. PubMed ID: 38679630
[TBL] [Abstract] [Full Text] [Related]
2. Isocitrate dehydrogenase 2 regulates the proliferation of triple-negative breast cancer through the ferroptosis pathway.
Zhang C; Zhou Y; Chen T; Bhushan S; Sun S; Zhang P; Yang Y
Sci Rep; 2024 Feb; 14(1):4732. PubMed ID: 38413708
[TBL] [Abstract] [Full Text] [Related]
3. Outcomes of Salvage Surgery Versus Non-Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma After Conversion Therapy with Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Antibody: A Multicenter Retrospective Study.
Wu JY; Wu JY; Fu YK; Ou XY; Li SQ; Zhang ZB; Zhou JY; Li B; Wang SJ; Chen YF; Yan ML
Ann Surg Oncol; 2024 May; 31(5):3073-3083. PubMed ID: 38316732
[TBL] [Abstract] [Full Text] [Related]
4. Integrated bulk and single-cell transcriptomes reveal pyroptotic signature in prognosis and therapeutic options of hepatocellular carcinoma by combining deep learning.
Liu Y; Li H; Zeng T; Wang Y; Zhang H; Wan Y; Shi Z; Cao R; Tang H
Brief Bioinform; 2023 Nov; 25(1):. PubMed ID: 38197309
[TBL] [Abstract] [Full Text] [Related]
5. A refined therapeutic plan based on the machine-learning prognostic model of liver hepatocellular carcinoma.
Sun X; Guo P; Wang N; Shi Y; Li Y
Comput Biol Med; 2024 Feb; 169():107907. PubMed ID: 38184863
[TBL] [Abstract] [Full Text] [Related]
6. [Clinicopathological features of intravascular large B-cell lymphoma and collision tumors of five cases].
Liu J; Liu GZ; Xia L; Wang HY; Zhang XF; Liu H
Zhonghua Bing Li Xue Za Zhi; 2024 Jan; 53(1):22-28. PubMed ID: 38178742
[No Abstract] [Full Text] [Related]
7. Prognostic nomograms for breast cancer with lung metastasis: a SEER-based population study.
Xie Y; Lei C; Ma Y; Li Y; Yang M; Zhang Y; Law KN; Wang N; Qu S
BMC Womens Health; 2024 Jan; 24(1):16. PubMed ID: 38172874
[TBL] [Abstract] [Full Text] [Related]
8. ER+/PR- phenotype exhibits more aggressive biological features and worse outcome compared with ER+/PR+ phenotype in HER2-negative inflammatory breast cancer.
Luo Y; Li Q; Fang J; Pan C; Zhang L; Xu X; Qian S; Zhao X; Hou L
Sci Rep; 2024 Jan; 14(1):197. PubMed ID: 38167641
[TBL] [Abstract] [Full Text] [Related]
9. Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer.
Wang W; Lei W; Fang Z; Jiang R; Wang X
BMC Cancer; 2024 Jan; 24(1):1. PubMed ID: 38166784
[TBL] [Abstract] [Full Text] [Related]
10. Clinical characteristics and prognosis of primary small cell carcinoma of the breast: a propensity score-matched, population-based study.
Yin L; Yin AH; Pu CC
BMJ Open; 2023 Dec; 13(12):e073841. PubMed ID: 38097248
[TBL] [Abstract] [Full Text] [Related]
11. Associations of circulating immunomarkers with the efficacy of immunotherapy for primary hepatic carcinoma.
Liu S; Xu W; Shu H; Dai Y; Du Y; Liu Y; Huang L; Sun G
Cancer Med; 2023 Dec; 12(24):21830-21848. PubMed ID: 38054365
[TBL] [Abstract] [Full Text] [Related]
12. Predicting diagnosis and survival of bone metastasis in breast cancer using machine learning.
Zhong X; Lin Y; Zhang W; Bi Q
Sci Rep; 2023 Oct; 13(1):18301. PubMed ID: 37880320
[TBL] [Abstract] [Full Text] [Related]
13. A Web-based Prediction Model for Early Death in Patients With Metastatic Triple-negative Breast cancer.
Pan WK; Ren SY; Zhu LX; Lin BC
Am J Clin Oncol; 2024 Feb; 47(2):71-80. PubMed ID: 37871164
[TBL] [Abstract] [Full Text] [Related]
14. Roles of long noncoding RNA in triple-negative breast cancer.
Das PK; Siddika A; Rashel KM; Auwal A; Soha K; Rahman MA; Pillai S; Islam F
Cancer Med; 2023 Oct; 12(20):20365-20379. PubMed ID: 37795578
[TBL] [Abstract] [Full Text] [Related]
15. Prolonged response to Tyrosine Kinase Inhibitors followed by Immunotherapy in metastatic hepatocellular carcinoma: A rare case report.
Roy P; Parthasarathy KM
J Cancer Res Ther; 2023; 19(5):1457-1461. PubMed ID: 37787330
[TBL] [Abstract] [Full Text] [Related]
16. Reclassification of therapeutic response of unresectable hepatocellular carcinoma to anti-angiogenic therapy and immunotherapy using alpha RECIST.
Xu Y; Yang Y; Ouyang J; Zhou Y; Li L; Ye F; Yang H; Huang Z; Zhou A; Zhang W; Zhou J; Zhao X; Zhao H
Eur Radiol; 2024 Apr; 34(4):2244-2255. PubMed ID: 37740779
[TBL] [Abstract] [Full Text] [Related]
17. Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings.
Ohama H; Hiraoka A; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Naganuma A; Kosaka H; Matono T; Shibata H; Aoki T; Tada F; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Iijima H; Kaibori M; Hiasa Y; Kudo M; Kumada T; ;
Oncology; 2023; 101(9):542-552. PubMed ID: 37552968
[TBL] [Abstract] [Full Text] [Related]
18. Inetetamab in combination with rapamycin and chemotherapy for trastuzumab-treated metastatic human epidermal growth factor receptor 2-positive breast cancer with abnormal activation of PI3K/Akt/mTOR pathway.
Wang A; Li C; Jiang Q; Jiang S
Cancer Rep (Hoboken); 2023 Sep; 6(9):e1864. PubMed ID: 37501598
[TBL] [Abstract] [Full Text] [Related]
19. [A Case of Breast Carcinoma That Changed Subtype to Squamous Cell Carcinoma after Chemotherapy].
Konishi K; Araya J; Nagabuchi M; Sakamoto T; Ogino J; Hirano S
Gan To Kagaku Ryoho; 2023 Jul; 50(7):825-827. PubMed ID: 37496230
[TBL] [Abstract] [Full Text] [Related]
20. Efficacy and safety of Lenvatinib-based combination therapies for patients with unresectable hepatocellular carcinoma: a single center retrospective study.
Huang J; Wang ZG; Tao QF; Yang Y; Yuan SX; Gu FM; Liu H; Pan ZY; Jiang BG; Lau WY; Zhou WP
Front Immunol; 2023; 14():1198562. PubMed ID: 37483609
[TBL] [Abstract] [Full Text] [Related]
[Next]
